Your browser doesn't support javascript.
loading
Healthcare resource utilization and related cost among hospitalized patients with prurigo nodularis: a retrospective cohort study using Italian health claims data.
Bahloul, Donia; Ronci, Gianluca; Isaman, Danielle L; Pedone, Maria P; Degli Esposti, Luca; Giacomini, Elisa; Veronesi, Chiara; Patruno, Cataldo; Chiricozzi, Andrea; Amerio, Paolo.
Afiliación
  • Bahloul D; Health Economic and Value Assessment, Sanofi, Gentilly, France - donia.bahloul@sanofi.com.
  • Ronci G; Sanofi SpA, Milan, Italy.
  • Isaman DL; Real World Evidence, Sanofi, Cambridge, MA, USA.
  • Pedone MP; Sanofi SpA, Milan, Italy.
  • Degli Esposti L; Department of Health Economics and Outcomes Research, CliCon S.r.l. Società Benefit, Bologna, Italy.
  • Giacomini E; Department of Health Economics and Outcomes Research, CliCon S.r.l. Società Benefit, Bologna, Italy.
  • Veronesi C; Department of Health Economics and Outcomes Research, CliCon S.r.l. Società Benefit, Bologna, Italy.
  • Patruno C; Section of Dermatology, Department of Health Sciences, Magna Graecia University, Catanzaro, Italy.
  • Chiricozzi A; Section of Dermatology, Department of Medicine and Translational Medicine, Sacred Heart Catholic University, Rome, Italy.
  • Amerio P; Unit of Dermatology, Department of Medical and Surgical Sciences, IRCCS A. Gemelli University Polyclinic Foundation, Rome, Italy.
Ital J Dermatol Venerol ; 159(5): 475-483, 2024 Oct.
Article en En | MEDLINE | ID: mdl-39250164
ABSTRACT

BACKGROUND:

Prurigo nodularis (PN) is a chronic, inflammatory skin disease characterized by intense itch. Little evidence exists on the burden of PN in Italy. This real-world analysis aimed to investigate the healthcare resource consumption and related direct costs of patients hospitalized for PN.

METHODS:

The analysis utilized the administrative databases of healthcare units that cover approximately 12 million inhabitants across Italy. Adult patients were included by ICD-9-CM=698.3 (lichen simplex chronicus; neurodermatitis circumscripta; PN) as proxy of PN diagnosis, from 01/2010 to 09/2021, and had 1 year of data availability before (baseline) and after (follow-up) hospitalization (index date). These patients were 12 matched by age, sex, and index date (year) to adults without such hospitalization in the baseline period (matched non-PN controls).

RESULTS:

The analysis comprised 295 PN-hospitalized patients, matched with 590 non-PN individuals (mean age 63.2 years, 43.7% female). At baseline, patients had a greater comorbidity burden than non-PN controls, including higher prevalence of hypertension (56.6% vs. 36.6%, respectively), dyslipidemia (26.4% vs. 18.0%), diabetes (24.4% vs. 12.5%) and mental health conditions (14.9% vs. 7.8%). During 1-year follow-up, PN-hospitalized patients had significantly higher resource consumption than matched controls, in terms of mean number of prescriptions most commonly prescribed in PN patients (5.1 vs. 1.9, P<0.001), other drugs (11.7 vs. 6.5, P<0.001), all-cause hospitalization (1.4 vs. 0.1, P<0.001) and outpatient services (5.4 vs. 2.5, P<0.001). Mean annual all-cause healthcare costs for patients over 1-year follow-up were € 3847 total (€ 875 drugs, € 2652 hospitalization, € 320 outpatient services), higher than those for the matched controls, of € 711 total (P<0.001) (€ 353 drugs, € 228 hospitalization, € 130 outpatient services).

CONCLUSIONS:

Patients hospitalized for PN had a higher comorbidity burden at baseline and greater healthcare resource consumption during 1-year follow-up compared to matched controls, with a 5.4-fold increase in all-cause healthcare costs, indicating substantial clinical burden and remaining unmet need in these patients.
Asunto(s)

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Prurigo / Hospitalización País/Región como asunto: Europa Idioma: En Revista: Ital J Dermatol Venerol Año: 2024 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Prurigo / Hospitalización País/Región como asunto: Europa Idioma: En Revista: Ital J Dermatol Venerol Año: 2024 Tipo del documento: Article